drugset
Drugs / rV-B7.1
last change Oct 2007 re-read 2 minutes ago

rV-B7.1

Vaccine

Developed for
prostate cancer · cutaneous melanoma
Investigated by
National Cancer Institute (NCI)

Trials 3 · a red edge is where a trial was stopped

today NCT00045227 · Ph 2 NCT00005916 · Ph 2 NCT00004148 · Ph 1
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00004148 Oct 1999 → Apr 2006 cutaneous melanoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00045227 Aug 2002 → Oct 2007 prostate cancer National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00005916 Jun 2000 → Dec 2005 prostate cancer National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as rV-B7.1 “using a recombinant vaccinia virus expressing B7.1 (rV-B7.1) for monthly intralesional vaccination of accessible melanoma lesions” PMID 15937544 ↗ Jun 2005
2

“rV that expresses the B7.1 costimulatory gene (rV-B7.1)” PMID 16489082 ↗ Feb 2006

NCT00005916 ↗
Action Deplete “Vaccines may make the body build an immune response to kill tumor cells.” NCT00045227 ↗
Modality Vaccine “rV-B7.1 vaccine” NCT00004148 ↗
Route Other “Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks” NCT00004148 ↗